Start Date

5-3-2024 9:10 AM

End Date

5-3-2024 11:00 AM

Description

Introduction

  • COVID-19 presented unique challenges for the care of immunocompromised individuals.
  • Patients with suppressed immune systems lack the ability to mount a robust response to vaccines, leading to an increased likelihood of developing severe COVID-19 responses and increased mortality.
  • Astra-Zeneca developed Evusheld, a monoclonal antibody (Tixagevimab/cilgavimab) as a COVID-19 prophylaxis to target the SARS-CoV-2 spike protein.1
  • In December 2023, the FDA enacted an Emergency Use Authorization (EUA) for Evusheld in immunocompromised individuals and TJUH developed a roll-out plan.2
  • Thomas Jefferson University Health (TJUH) distributed the drug using a tiering system that ranked the degrees of immunocompromising conditions for priority administration.

Research Question: How effective was the TJUH roll out program at distributing a medication in limited supply under the constraints of a pandemic?

Hypothesis: The tiering system will successfully allocate immunocompromised patients Evusheld for Covid-19. Analyzing the program for supplying Evusheld to TJUH will provide insights for effective novel

Keywords

Evusheld, COVID-19, prophylaxis, roll-out program, immunocompromised, resource allocation, monoclonal antibody

Comments

Presented at the 2024 Jefferson Health Equity and Quality Improvement (HEQI) Summit.

Download

Share

COinS
 
May 3rd, 9:10 AM May 3rd, 11:00 AM

Optimizing Resource Allocation of a COVID-19 Prophylactic in Immunocompromised Hosts

Introduction

  • COVID-19 presented unique challenges for the care of immunocompromised individuals.
  • Patients with suppressed immune systems lack the ability to mount a robust response to vaccines, leading to an increased likelihood of developing severe COVID-19 responses and increased mortality.
  • Astra-Zeneca developed Evusheld, a monoclonal antibody (Tixagevimab/cilgavimab) as a COVID-19 prophylaxis to target the SARS-CoV-2 spike protein.1
  • In December 2023, the FDA enacted an Emergency Use Authorization (EUA) for Evusheld in immunocompromised individuals and TJUH developed a roll-out plan.2
  • Thomas Jefferson University Health (TJUH) distributed the drug using a tiering system that ranked the degrees of immunocompromising conditions for priority administration.

Research Question: How effective was the TJUH roll out program at distributing a medication in limited supply under the constraints of a pandemic?

Hypothesis: The tiering system will successfully allocate immunocompromised patients Evusheld for Covid-19. Analyzing the program for supplying Evusheld to TJUH will provide insights for effective novel